Fish oil, omega-3, EPA, DHA: which number matters?
Is 1,000 mg fish oil the same as 1,000 mg omega-3?
On this page
Omega-3s are a family of fatty acids. ALA is an essential fat found in plant foods such as flaxseed and some oils; EPA and DHA occur in fish, seafood and some algae-derived products. The body converts only small amounts of ALA into EPA and DHA. Foods, ordinary supplements and prescription products are distinct exposures.[1]
What does this actually mean?
Fish oil is the ingredient; omega-3 is a family
Fish oil contains a mixture of fats. EPA and DHA are two long-chain omega-3 fatty acids within that mixture; the total oil weight is not their combined weight. Plant foods such as flax supply mainly ALA, another omega-3. These names are related, but a gram of one should not silently become a gram of another when comparing labels.[10]
Read the smaller numbers
On a hypothetical label, 1,000 mg fish oil containing 300 mg EPA and 200 mg DHA supplies 500 mg EPA plus DHA, not 1,000 mg. This arithmetic is an illustration, not a recommended dose. Check whether those amounts are for one capsule or several. A label-database study found substantial variation in EPA and DHA amounts and serving requirements.[11]
A heart-health slogan is a different kind of statement
A 2023 US label study found that most sampled fish-oil products carried health claims, often general support language. The study inspected labels, not whether users had fewer heart attacks. “Supports heart health” does not identify the tested population, the ingredient formulation or the outcome, and it should not be read as proof of disease prevention.[12]
Why prescription results do not transfer automatically
Prescription omega-3 medicines have specified formulations and indications. A high-purity EPA medicine is not interchangeable with every EPA–DHA supplement. Large trials also studied different patients and background treatment. A favorable result in a selected high-risk group cannot establish that an ordinary capsule improves outcomes for every otherwise healthy shopper.[10]
Amount is only part of the evidence
Trials of different omega-3 formulations have produced different cardiovascular results. Lowering triglycerides and preventing clinical events are separate endpoints. More concentrated does not automatically mean a better net outcome: benefits, side effects and the reason for use all matter. Do not interpret a large number as a personal treatment plan or replace a prescribed medicine with a supplement.[5]
What to compare on the shelf
Compare the separately listed EPA and DHA amounts, serving size, source and whether the product is a supplement or prescription medicine. Calculate the cost for the same stated EPA–DHA amount rather than for the same capsule count. A quality test can address specified contents; it cannot turn a broad wellness claim into a proven clinical benefit.[11][12]
What the label and product type mean
Total fish-oil weight differs from its EPA and DHA content.[2]
Products vary in composition, and algae-derived products provide an alternative source of long-chain omega-3s. The US dietary reference system specifies an adequate intake for ALA, but does not establish one universal EPA/DHA requirement for everyone.[1]
Harms and relevance beyond heart disease
Common supplement complaints include unpleasant taste and gastrointestinal symptoms. High-dose trials have raised atrial-fibrillation concerns, and medicine interactions require context, particularly with anticoagulants. The evidence for one cardiovascular indication cannot be extended automatically to brain health, depression, dry eyes, pregnancy or longevity. Those require their own outcome-specific evidence.[2]
Different findings answer different omega-3 questions
| Finding | What it establishes | What it does not establish |
|---|---|---|
| A product’s EPA/DHA amount | A description of its fatty-acid ingredients. | Not a universal heart-event benefit.[1] |
| Lower triglycerides | A change in a blood lipid measure. | Not interchangeable with every clinical outcome.[6] |
| A specified prescription indication | A medicine used for defined treatment or risk-reduction purposes. | Not automatic eligibility for every supplement user.[6] |
| Atrial fibrillation findings | A rhythm-related outcome in particular trials and groups. | Not the same as a heart-attack outcome.[7] |
A similar ingredient name does not make products interchangeable
MedlinePlus describes icosapent ethyl as a lipid-regulating prescription medicine used for triglycerides and cardiovascular-risk reduction in certain adults. Its clinical purpose, monitoring and precautions matter. A general fish-oil label is not itself a prescription assessment, and a laboratory change does not guarantee all cardiovascular outcomes improve.[6]
The medicine information also asks about rhythm problems, other illnesses and other products being taken. Assessing potential benefits and harms is more specific than deciding that all omega-3 products are harmless because a fatty acid is a nutrient. This explanation does not substitute a supplement for a prescribed medicine.[6]
A preprint and a later expanded paper are one developing evidence stream
A December 2025 preprint examined atrial fibrillation by dose and cardiovascular-risk group in older adults. It reported a statistically clear increase in its high-risk, high-dose subgroup, while other subgroup estimates were not significant. The latter finding is not proof of zero risk, and the subgroup pattern should not become a personal dose rule.[7]
The indexed record links a later 2026 publication with an expanded trial set. The preprint and publication are related versions, not independent replication. Final publication metadata was located, but its full final analyses were not inspected here. This addition therefore labels the earlier findings as preliminary and does not relabel them as the complete current synthesis.[8][7]
Birth timing and later development are separate outcomes
The ORIP trial defined early preterm delivery as birth before 34 completed weeks of pregnancy. That outcome differs from a maternal fatty-acid blood measurement or a child’s later developmental score.[13]
Evidence & uncertainty
The cardiovascular evidence does not support one verdict for every omega-3 product. A selected prescription EPA trial reduced events, while a different high-dose EPA/DHA trial did not. Dose, formulation, baseline risk, background treatment and comparator differ; triglyceride lowering alone does not prove fewer heart attacks.[2]
Selected-source overview · Independent review pendingPublished questions
Are ALA, EPA and DHA interchangeable?
Selected-source overview · Independent review pending. Read the evidence context.
They are different omega-3 fatty acids. Only a small amount of dietary ALA is converted into EPA and DHA; equal gram amounts therefore do not provide the same exposure.[1]
Evidence behind this answer
- Omega-3 Fatty Acids — Consumer
agency explanation · 2022
Selected relevant page text or publication abstract inspected · ALA/EPA/DHA; limited conversion; sources, products and dietary reference values
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does ordinary fish oil reliably prevent heart attacks in everyone?
Selected-source overview · Independent review pending. Read the evidence context.
VITAL did not significantly reduce its primary major-cardiovascular-event composite. A selected high-risk prescription-drug trial is not a demonstration of universal benefit from ordinary supplements.[3]
Evidence behind this answer
- Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
randomized trial · 2019
Indexed primary-source passages; direct retrieval unavailable · Indexed primary abstract; 25,871 adults; primary outcomes
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
What was the absolute benefit in REDUCE-IT?
Selected-source overview · Independent review pending. Read the evidence context.
The primary composite event occurred in 17.2% with prescription EPA versus 22.0% with its comparator, a 4.8 percentage-point difference over median 4.9-year follow-up. Participants already had elevated cardiovascular risk and were taking statins.[4]
Evidence behind this answer
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
randomized trial · 2019
Indexed primary-source passages; direct retrieval unavailable · Indexed primary abstract; selection, intervention, follow-up, primary composite
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Why do omega-3 trials appear to disagree?
Selected-source overview · Independent review pending. Read the evidence context.
They test different formulations, populations, comparators and doses. REDUCE-IT and STRENGTH are not a direct EPA-versus-EPA/DHA comparison; no single explanation is conclusively established.[2]
Evidence behind this answer
- Omega-3 Fatty Acids — Health Professional Fact Sheet
agency evidence summary · Date not stated
Selected relevant page text or publication abstract inspected · Trial differences, mineral-oil comparator, safety and medication interactions
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did high-dose EPA plus DHA reduce events in STRENGTH?
Selected-source overview · Independent review pending. Read the evidence context.
No significant reduction in its primary cardiovascular composite was observed. This applies to that tested formulation and high-risk statin-treated population, rather than every possible food or product.[5]
Evidence behind this answer
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events: STRENGTH
randomized trial · 2020
Selected relevant page text or publication abstract inspected · Abstract; primary results; Table 2 atrial fibrillation; early stopping; follow-up
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is an omega-3 capsule equivalent to eating fish?
Selected-source overview · Independent review pending. Read the evidence context.
No. Fish is a food containing other nutrients and can replace another food in the diet. A supplement or prescription preparation has a particular composition and is tested as a separate intervention.[1]
Evidence behind this answer
- Omega-3 Fatty Acids — Consumer
agency explanation · 2022
Selected relevant page text or publication abstract inspected · ALA/EPA/DHA; limited conversion; sources, products and dietary reference values
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does lowering triglycerides prove every cardiovascular outcome improves?
Selected-source overview · Independent review pending. Read the evidence context.
No. A lipid measurement and particular clinical events are different outcomes. A medicine’s tested purpose and population matter.[6]
Evidence behind this answer
- Icosapent Ethyl
agency medicine explanation · Date not stated
Selected relevant official page passages inspected · Specified indications and rhythm/medicine precautions
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does a prescription omega-3 indication automatically apply to every fish-oil user?
Selected-source overview · Independent review pending. Read the evidence context.
No. MedlinePlus describes specified uses in certain adults. Product, clinical context and precautions need their own assessment.[6]
Evidence behind this answer
- Icosapent Ethyl
agency medicine explanation · Date not stated
Selected relevant official page passages inspected · Specified indications and rhythm/medicine precautions
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does a nonsignificant omega-3 rhythm-risk result prove zero risk?
Selected-source overview · Independent review pending. Read the evidence context.
No. The selected preprint’s subgroup findings do not establish absence of risk. Publication version and population must remain explicit.[7]
Evidence behind this answer
- Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 34 Trials including 114,326 Individuals
original preprint meta analysis · 2025
Indexed original preprint methods/results and later-publication link inspected · Indexed original methods, risk/dose subgroup results, update link and disclosures
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Are an omega-3 preprint and its later expanded publication independent replication?
Selected-source overview · Independent review pending. Read the evidence context.
No. They are related versions of a developing synthesis. They should not be counted as separate independent confirmations.[7][8]
Evidence behind this answer
- Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 34 Trials including 114,326 Individuals
original preprint meta analysis · 2025
Indexed original preprint methods/results and later-publication link inspected · Indexed original methods, risk/dose subgroup results, update link and disclosures - Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials including 114,592 Individuals
published review bibliographic record · 2026
Indexed publication metadata only; direct record and final analyses unavailable · July/August 2026 publication metadata and expanded trial-set title
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is 1,000 mg fish oil the same as 1,000 mg omega-3?
Selected-source overview · Independent review pending. Read the evidence context.
No. Total fish-oil weight includes fats other than EPA and DHA. Look for the separately listed omega-3 amounts and serving size. For example, 300 mg EPA plus 200 mg DHA equals 500 mg EPA–DHA, even when the oil itself weighs 1,000 mg.[11]
Evidence behind this answer
- Analysis of Omega-3 Fatty Acid Content in Fish Oil Products
original label analysis · 2021
Original indexed abstract inspected; full text not retrieved · Abstract Methods: label amounts, serving sizes and units needed
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does a study of fish-oil labels show that the products prevent heart attacks?
Selected-source overview · Independent review pending. Read the evidence context.
No. The 2023 label study counted claims and ingredient amounts; it did not randomly assign supplements and measure heart attacks. It helps explain marketing variability, while clinical benefits require different evidence.[12]
Evidence behind this answer
- Health Claims and Doses of Fish Oil Supplements in the US
original cross sectional label study · 2023
Selected original full-text sections inspected · Abstract Methods, Results and Introduction on claim types
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does taking DHA during pregnancy improve a child’s language development?
Selected-source overview · Independent review pending. Read the evidence context.
In one selected randomized trial, average cognitive and language scores did not clearly improve at eighteen months. That does not predict one child’s development or settle later ages, and this is not a complete synthesis of every trial.[15]
Evidence behind this answer
- Effect of DHA Supplementation During Pregnancy on Maternal Depression and Neurodevelopment of Young Children: A Randomized Controlled Trial
original randomized trial · 2010
Original JAMA full article retrieved via DOI with Firecrawl after native DOI/PubMed failures. Selected methods/selection, results, limits and disclosures read. 726 selected children, 694 actually assessed. Adopted primary mean developmental results and mixed secondary context, not a maternal-depression treatment conclusion, all-age verdict or prenatal dose. · Complete abstract; child-follow-up selection/statistical analysis; Results flow; developmental primary means; Comment; funding/sponsor role/disclosures
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Selected-study outcomes
These views show selected findings from abstracts, publication records or selected full-text passages. Access is stated for each record. Complete synthesis and independent appraisal remain pending.
Selected study · review incomplete
Omega-3 and vascular events in diabetes
The trial did not show a clear reduction in serious vascular events.[9]
This preparation and prevention setting differ from prescription purified-EPA trials.
- Population
- 15,480 adults with diabetes without atherosclerotic CVD
- Intervention/exposure
- 1-g capsule containing omega-3; active amounts not extracted
- Comparison
- Matching olive-oil placebo
- Follow-up
- Mean 7.4 years
- Setting
- UK ASCEND
| Measure | Reported result |
|---|---|
| Rate ratio | 0.97; 95% CI 0.87–1.08; p 0.55 |
| Intervention counts | 689 events; 8.9% reported; denominator not extracted |
| Comparison counts | 712 events; 9.2% reported; denominator not extracted |
Harms: Not extracted.
Stated population/comparison only.
Extraction details
Access: Indexed primary abstract plus original-study author repository
Funding: Not extracted.
Conflicts: Not extracted.
Query: "Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus" "15,480"
Certainty ungraded. Appraisal and qualified review pending.
Three important trials ask different questions
VITAL tested a daily marine omega-3 supplement in 25,871 US adults, men aged at least 50 and women at least 55, without selecting for high cardiovascular risk. Over a median 5.3 years, it did not significantly reduce the primary composite of major cardiovascular events or invasive cancer. Selected secondary findings are not equivalent to a positive primary result.[3]
REDUCE-IT studied 8,179 statin-treated people with elevated triglycerides and established cardiovascular disease or diabetes with additional risk factors. Prescription icosapent ethyl, a purified EPA product, was compared with mineral oil. Over a median 4.9 years, the primary composite event occurred in 17.2% versus 22.0%: a 4.8 percentage-point absolute difference in that population. This is not evidence that an ordinary supplement has the same effect.[4]
STRENGTH studied 13,078 statin-treated, high-risk participants using an EPA/DHA carboxylic-acid formulation versus corn oil. The primary composite occurred in 12.0% versus 12.2%; the hazard ratio was 0.99 (95% CI 0.90–1.09). The trial stopped early for low probability of benefit. Gastrointestinal adverse effects and atrial fibrillation were more frequent in the omega-3 group.[5]
These trials were not a head-to-head test of EPA against EPA/DHA. NIH ODS identifies formulation, population and comparator differences as possible explanations. Mineral oil’s effects on biomarkers complicate interpretation of REDUCE-IT’s effect size. Neither simply pooling unlike products nor declaring one isolated difference the proven explanation resolves the disagreement.[2]
A broad pregnancy trial did not confirm an overall reduction
The 2019 Australian ORIP trial randomized 5,544 pregnancies. Early preterm delivery occurred in 2.2% with the DHA-rich fish-oil intervention versus 2.0% with control oil; the difference was not statistically clear. Minor gastrointestinal effects were more common with supplementation. The intervention ended by 34 weeks of pregnancy. The result does not compare every prenatal product.[13]
Infant development required its own assessment
The earlier DOMInO trial randomized 2,399 singleton pregnancies to DHA-rich fish oil or control. Researchers assessed 694 selected children at eighteen months; mean cognitive and language scores did not clearly improve. The follow-up sample included preterm children and randomly selected term children, rather than all offspring. Secondary developmental findings were mixed; later ages need separate evidence.[15]
Baseline-status findings were exploratory
A singleton-pregnancy reanalysis suggested benefit at lower baseline omega-3 status and an opposite pattern at higher status. It involved multiple post hoc comparisons without multiplicity adjustment. It is related evidence from ORIP, not independent replication or a personal blood-test threshold for starting supplements.[14]
A biological rationale is not a developmental guarantee
The maternal trial size is not the infant-assessment sample size. Measures at eighteen months also do not settle later intelligence or predict one child’s development. These supplementation comparisons do not compare all benefits and risks of eating fish.[15]
How these sources are connected
Reference counts do not count independent studies. Known relationships in this article:
- VITAL trial reports: These reports reuse participants from the same factorial trial. Different outcomes or interventions do not make them independent trial populations.[3]
These are selected documented relationships, not a complete audit of overlap among all cited studies.
References
- Omega-3 Fatty Acids — Consumer
Agency explanation
NIH Office of Dietary Supplements · Content/publication date: 2022
Accessed: 2026-10-06 UTC · Selected relevant page text or publication abstract inspected
Cited sections: ALA/EPA/DHA; limited conversion; sources, products and dietary reference values - Omega-3 Fatty Acids — Health Professional Fact Sheet
Agency evidence summary
NIH Office of Dietary Supplements · Content/publication date: not stated
Accessed: 2026-10-06 UTC · Selected relevant page text or publication abstract inspected
Cited sections: Trial differences, mineral-oil comparator, safety and medication interactions - Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Randomized trial
Manson JE and colleagues · Content/publication date: 2019
Accessed: 2026-10-06 UTC · Indexed primary-source passages; direct retrieval unavailable
Cited sections: Indexed primary abstract; 25,871 adults; primary outcomesVITAL omega-3 factorial comparison; shares participants with the vitamin D reports.
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Randomized trial
Bhatt DL and colleagues · Content/publication date: 2019
Accessed: 2026-10-06 UTC · Indexed primary-source passages; direct retrieval unavailable
Cited sections: Indexed primary abstract; selection, intervention, follow-up, primary compositeREDUCE-IT. Trial medication was prescription icosapent ethyl; comparator mineral oil. Industry-funded trial; no independent risk-of-bias appraisal completed here.
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events: STRENGTH
Randomized trial
Nicholls SJ and colleagues · Content/publication date: 2020
Accessed: 2026-10-06 UTC · Selected relevant page text or publication abstract inspected
Cited sections: Abstract; primary results; Table 2 atrial fibrillation; early stopping; follow-upSTRENGTH. Industry-funded trial; selected sections inspected, not an independent full risk-of-bias appraisal.
- Icosapent Ethyl
Agency medicine explanation
MedlinePlus / American Society of Health-System Pharmacists · Content/publication date: not stated
Accessed: 2026-10-07 UTC · Selected relevant official page passages inspected
Cited sections: Specified indications and rhythm/medicine precautions - Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 34 Trials including 114,326 Individuals
Original preprint meta analysis
Abuknesha NR and colleagues · Content/publication date: 2025
Accessed: 2026-10-07 UTC · Indexed original preprint methods/results and later-publication link inspected
Cited sections: Indexed original methods, risk/dose subgroup results, update link and disclosuresPreprint, not the final 2026 synthesis. Disclosures include omega-3 product and fatty-acid-testing business interests. No independent full bias or subgroup-interaction appraisal.
- Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials including 114,592 Individuals
Published review bibliographic record
Abuknesha NR and colleagues · Content/publication date: 2026
Accessed: 2026-10-07 UTC · Indexed publication metadata only; direct record and final analyses unavailable
Cited sections: July/August 2026 publication metadata and expanded trial-set titleLocated as the later version. No final effect estimates are derived from uninspected results; the preprint is not relabelled as the final paper.
- Omega-3 and vascular events in diabetes
Randomized controlled trial
ASCEND Study Collaborative Group · Content/publication date: 2018
Accessed: 2026-10-14 UTC · Indexed primary abstract plus original-study author repository
Cited sections: Abstract: Methods/ResultsExtraction; independent review pending.
- Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not Interchangeable
Clinical review
Original publication authors · Content/publication date: 2016
Accessed: 2026-10-15 UTC · Original indexed abstract inspected; full text not retrieved
Cited sections: Abstract Purpose and Conclusions on formulations and substitutionSelected evidence; outcome and population boundaries apply.
- Analysis of Omega-3 Fatty Acid Content in Fish Oil Products
Original label analysis
Original publication authors · Content/publication date: 2021
Accessed: 2026-10-15 UTC · Original indexed abstract inspected; full text not retrieved
Cited sections: Abstract Methods: label amounts, serving sizes and units neededSelected evidence; outcome and population boundaries apply.
- Health Claims and Doses of Fish Oil Supplements in the US
Original cross sectional label study
Original publication authors · Content/publication date: 2023
Accessed: 2026-10-15 UTC · Selected original full-text sections inspected
Cited sections: Abstract Methods, Results and Introduction on claim typesSelected evidence; outcome and population boundaries apply.
- A Randomized Trial of Prenatal n−3 Fatty Acid Supplementation and Preterm Delivery
Original randomized trial
Makrides M and colleagues · Content/publication date: 2019
Accessed: 2026-10-20 UTC · Original NEJM full text retrieved with Firecrawl after native error. Selected methods, flow, primary result, harms and limitations read. 5,544 pregnancies in 5,517 women; primary analysis 5,486 after imputation, not one unique participant per pregnancy. No dose or start/stop schedule adopted. Prespecified baseline DHA subgroup did not establish interaction; later exploratory reanalysis is separate but grouped conservatively.
Cited sections: Complete abstract; Trial Design/Oversight; eligibility; participant flow/imputation; primary outcome; Safety and Side Effects; discussion and disclosuresRelated trial reports; public funding, donated capsules and author industry/patent interests disclosed.
- Omega-3 fatty acid supplementation in pregnancy—baseline omega-3 status and early preterm birth: exploratory analysis of a randomised controlled trial
Original exploratory trial reanalysis
Simmonds LA and colleagues · Content/publication date: 2020
Accessed: 2026-10-20 UTC · Original university-hosted published PDF retrieved. Selected complete methods/results/limitations and disclosures read. Analysis included 5,070 singleton pregnancies with baseline dried blood spot and outcomes; 5% missing. Candidate biomarkers/thresholds were explored with no multiplicity adjustment, not a validated personal testing rule. Shares original ORIP allowance, despite distinct publication.
Cited sections: Original published 7-page PDF: abstract; singleton selection/statistical analysis; multiplicity; results; strengths/limitations; discussion; funding/disclosuresRelated trial reports; public funding, donated capsules and author industry/patent interests disclosed.
- Effect of DHA Supplementation During Pregnancy on Maternal Depression and Neurodevelopment of Young Children: A Randomized Controlled Trial
Original randomized trial
Makrides M and colleagues; DOMInO Investigative Team · Content/publication date: 2010
Accessed: 2026-10-20 UTC · Original JAMA full article retrieved via DOI with Firecrawl after native DOI/PubMed failures. Selected methods/selection, results, limits and disclosures read. 726 selected children, 694 actually assessed. Adopted primary mean developmental results and mixed secondary context, not a maternal-depression treatment conclusion, all-age verdict or prenatal dose.
Cited sections: Complete abstract; child-follow-up selection/statistical analysis; Results flow; developmental primary means; Comment; funding/sponsor role/disclosuresPublic funding; donated capsules and author nutrition-industry advisory roles disclosed.
Scope & review
- Population
- General older-adult prevention versus selected statin-treated high-risk populations
- Exposure or intervention
- ALA, EPA/DHA supplements and prescription icosapent ethyl
- Comparison
- Placebo oils differing across trials; not a direct product comparison
- Outcomes
- Cardiovascular composites, triglycerides, cancer, adverse effects
- Timeframe
- Trial-specific follow-up of several years
- Jurisdiction
- US dietary references; international trial populations; medicine indications vary
Targeted educational explanation from selected official sources and primary publications. Not an exhaustive systematic review, individualized treatment plan, or qualified medical signoff. The edition 3.7 source check applies to selected additions; older references retain their individual access dates.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-06 UTC: Added definitions, distinctions, research context, harms, population limits and sourced answers. Qualified review remains pending.
- 2026-10-07 UTC: Edition 3.7: added definitions, product distinctions and sourced questions; existing anchors and source-access dates preserved. Qualified review remains pending.
- 2026-10-15 UTC: Added the plain-English series explanation with definitions, distinctions, practical questions and selected primary sources; qualified review remains pending.
- 2026-10-20 UTC: Added bounded, source-supported explanations after fresh full-record and canonical-neighbor reads. Original content preserved; assumptions, access, selected populations and remaining scope explicit. Qualified review pending.
What this article still leaves open
- Outcome-specific evidence for pregnancy, cognition, eye disease and psychiatric uses.
- How formulation and comparator differences explain conflicting cardiovascular results.
- Complete final 2026 rhythm-risk analysis, subgroup-interaction and absolute-harm appraisal, with overlapping reviews deduplicated.
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
More in the plain-English series
Keep making sense of it.
Explore Supplements explanations See every explanationExplore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.